Association of CD44 gene polymorphism with survival of NSCLC and risk of bone metastasis

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 2694-2700

  Liu, Yaosheng ^a   Qing, Haifeng ^a   Su, Xiuyun ^a   Wang, Cheng ^a   Li, Zhuo ^a   Liu, Shubin ^a  

^a Beijing 307 Hospital   (China)

Author keywords

Bone diseases; Carcinoma; Non small cell lung; Polymorphism; Single nucleotide; Survival analysis

Indexed keywords

ADULT; ALLELE; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CD44 GENE; CLINICAL FEATURE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER; AGED; BONE TUMOR; CYTOLOGY; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; TREATMENT OUTCOME;

CD44 PROTEIN, HUMAN; HERMES ANTIGEN;

AGED; ALLELES; ANTIGENS, CD44; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84941197663     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894357     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010; 127(12): 2893–917
2. Bi N, Yang M, Zhang L et al: Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res, 2010; 16(8): 2383–90
3. Gandara D, Narayan S, Lara PN Jr et al: Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res, 2005; 11(13 Pt 2): 5057s–62s
4. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. Cancer J Clin, 2013; 63(1): 11–30
5. Hashisako M, Wakamatsu K, Ikegame S et al: Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. Tohoku J Exp Med, 2012; 228(2): 163–68
6. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 2006; 12(20 Pt 2): 6243s–49s
7. Decroisette C, Monnet I, Berard H et al: Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol, 2011; 6(3): 576–82
8. Tsuya A, Kurata T, Tamura K, Fukuoka M: Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer, 2007; 57(2): 229–32
9. Kozlow W, Guise TA: Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia, 2005; 10(2): 169–80
10. Di Maio M, Gridelli C, Gallo C et al: Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer, 2004; 90(12): 2288–96
11. Cetin K, Christiansen CF, Jacobsen JB et al: Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish populationbased cohort study. Lung Cancer, 2014; 86(2): 247–54
12. Liu L, Chen X, Wang Y et al: Notch3 is important for TGF-beta-induced epithelial- mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1. Cancer Gene Ther, 2014; 21(9): 364–72
13. Pockett RD, Castellano D, McEwan P et al: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl), 2010; 19(6): 755–60
14. Chen Y, Liu H, Wu W et al: Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res, 2013; 32: 45
15. Rafrafi A, Kaabachi S, Kaabachi W et al: CCR2-64I polymorphism is associated with non-small cell lung cancer in Tunisian patients. Hum Immunol, 2015; 76(5): 348–54
16. Bhat IA, Naykoo NA, Qasim I et al: Association of interleukin 1 beta (IL- 1beta) polymorphism with mRNA expression and risk of non small cell lung cancer. Meta Gene, 2014; 2: 123–33
17. Geredeli C, Artac M, Yildirim S et al: Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with earlystage non-small cell lung cancer. Tumour Biol, 2015 [Epub ahead of print]
18. Goodfellow PN, Banting G, Wiles MV et al: The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol, 1982; 12(8): 659–63
19. Bourguignon LY, Zhu D, Zhu H: CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci, 1998; 3: d637–49
20. Rafi A, Nagarkatti M, Nagarkatti PS: Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood, 1997; 89(8): 2901–8
21. Chen D, McKallip RJ, Zeytun A et al: CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J Immunol, 2001; 166(10): 5889–97
22. Ko YH, Won HS, Jeon EK et al: Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer, 2011; 11: 340
23. Arch R, Wirth K, Hofmann M et al: Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science, 1992; 257(5070): 682–85
24. Marhaba R, Zoller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol, 2004; 35(3): 211–31
25. Hill A, McFarlane S, Johnston PG, Waugh DJ: The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett, 2006; 237(1): 1–9
26. Luo Z, Wu RR, Lv L et al: Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol, 2014; 7(7): 3632–46
27. Brown RL, Reinke LM, Damerow MS et al: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest, 2011; 121(3): 1064–74
28. Clarke MR, Landreneau RJ, Resnick NM et al: Prognostic significance of CD44 expression in adenocarcinoma of the lung. Clin Mol Pathol, 1995; 48(4): M200–4
29. Bertaux-Skeirik N, Feng R, Schumacher MA et al: CD44 plays a functional role in Helicobacter pylori-induced epithelial cell proliferation. PLoS Pathog, 2015; 11(2): e1004663
30. Dong C, Ye DX, Zhang WB, Pan HY et al: Overexpression of c-fos promotes cell invasion and migration via CD44 pathway in oral squamous cell carcinoma. J Oral Pathol Med, 2015; 44(5): 353–60
31. Zhao S, He JL, Qiu ZX et al: Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pac J Cancer Prev, 2014; 15(16): 6761–66
32. Quan YH, Kim B, Park JH et al: Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. Exp Lung Res, 2014; 40(10): 475–84
33. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM: Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res, 2007; 67(20): 9609–12
34. Morley M, Molony CM, Weber TM et al: Genetic analysis of genome-wide variation in human gene expression. Nature, 2004; 430(7001): 743–47
35. Chou YE, Hsieh MJ, Chiou HL et al: CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. Biomed Res Int, 2014; 2014: 231474
36. Chou YE, Hsieh MJ, Hsin CH et al: CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan. PLoS One, 2014; 9(4): e93692
37. Tulsyan S, Agarwal G, Lal P et al: CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population. PLoS One, 2013; 8(8): e71073
38. Ahuja V, Coleman RE, Herndon J, Patz EF Jr: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer, 1998; 83(5): 918–24
39. Livak KJ: Allelic discrimination using fluorogenic probes and the 5’ nuclease assay. Genet Anal, 1999; 14(5–6): 143–49
40. Huang SM, Cheung CW, Chang CS et al: Phloroglucinol derivative MCPP induces cell apoptosis in human colon cancer. J Cell Biochem, 2011; 112(2): 643–52
41. Song Z, Zhang Y: Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. Med Oncol, 2014; 31(4): 898
42. Deberne M, Ropert S, Billemont B et al: Inaugural bone metastases in nonsmall cell lung cancer: a specific prognostic entity? BMC Cancer, 2014; 14: 416
43. Sharma KL, Yadav A, Gupta A et al: Association of genetic variants of cancer stem cell gene CD44 haplotypes with gallbladder cancer susceptibility in North Indian population. Tumour Biol, 2014; 35(3): 2583–89
44. Xiao M, Hu S, Zhang L et al: Polymorphisms of CD44 gene and nasopharyngeal carcinoma susceptibility in a Chinese population. Mutagenesis, 2013; 28(5): 577–82
45. Taira N, Kawabata T, Ichi T et al: Long-term survival after surgical treatment of metachronous bilateral adrenal metastases of non-small cell lung carcinoma. Am J Case Rep, 2014; 15: 444–46
46. Herrlich P, Morrison H, Sleeman J et al: CD44 acts both as a growth- and invasiveness- promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci, 2000; 910: 106–18
47. Kanaji N, Tadokoro A, Watanabe N et al: Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib. Am J Case Rep, 2014; 15: 480–84
48. Ramasami S, Kerr KM, Chapman AD et al: Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol, 2000; 192(4): 427–32
49. Vazquez A, Grochola LF, Bond EE et al: Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res, 2010; 70(1): 172–80
50. Jiang L, Deng J, Zhu X et al: CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res, 2012; 14(4): R105